Is it the blood pressure or the blood vessel?

Journal of the American Society of Hypertension

Volumn 1, Issue 1, 2007, Pages 5-16

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

antihypertensive drugs; Blood pressure; endothelial dysfunction; morbid events; vascular resistance; vascular structure

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PLACEBO; RENIN INHIBITOR;

ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; MICROCIRCULATION; PATHOLOGICAL ANATOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VASODILATATION;

EID: 34248155268     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2006.11.001     Document Type: Article

References (72)

1. Cohn J.N. Arteries, myocardium, blood pressure, and cardiovascular risk: towards a revised definition of hypertension. J Hypertens 16 (1998) 2117-2124
2. Giles T.D., Berk B.C., Black H.R., et al., Hypertension Writing Group. Expanding the definition and classification of hypertension. J Clin Hypertens 7 (2005) 505-512
3. Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362 (2003) 1527-1535
4. Verdecchia P., Reboldi G., Angeli F., et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 (2005) 386-392
5. Sever P.S., and Poulter N.R. Blood pressure reduction is not the only determinant of outcome. Circulation 113 (2006) 2754-2763
6. Elliott W.J., Jonsson C., and Black H.R. It is not beyond the blood pressure; it is the blood pressure. Circulation 113 (2006) 2763-2772
7. Mulvaney M.J. Remodeling of resistance vessel structure in essential hypertension. Curr Opin Nephrol Hypertens 2 (1993) 77-81
8. Franklin S.S., Gustin W.I.V., Wong N.D., et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 96 (1997) 308-315
9. Cohn J.N. Haemodynamic effects of beta blockers. Drugs 25 suppl 2 (1983) 100-102
10. Neaton J.D., Wentworth D., and Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 152 (1992) 56-64
11. Kannel W.B. Blood pressure as a cardiovascular risk factor. JAMA 275 (1996) 1571-1576
12. Quyyumi A.A., Dakak N., Andrews N.P., et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 95 (1995) I1747-I1755
13. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
14. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 suppl 2A (2002) 3A-10
15. Morishita R., Higaki J., Miyazaki M., and Ogihara T. Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension 19 suppl 2 (1992) S62-S67
16. Linder L., Kiowski W., Bühler F.R., and Lüscher T.F. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation 81 (1990) 1762-1767
17. Panza J.A., Casino P.R., Kilcoyne C.M., and Quyyumi A.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87 (1993) 1468-1474
18. Devereux R.B., Savage D.D., Sachs I., and Laragh J.H. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol 51 (1983) 171-176
19. Schelling P., Fisher H., and Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy?. J Hypertens 9 (1991) 3-5
20. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 14 (2001) 174-182
21. Pachori A.S., Numan M.T., Ferrario C.M., Diz D.M., Raizada M.K., and Katovich M.J. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 39 (2002) 969-975
22. Everett A.D., Tufro-McReddie A., Fisher A., and Gomez R.A. Angiotensin inhibitors regressed cardiac hypertrophy and transforming growth factor-β 1 expression. Hypertension 23 (1994) 587-592
23. Prabhu S.D. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 94 (2004) 1155-1157
24. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson Jr. S.K., and Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340 (1999) 14-22
25. Lakatta E.G., and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular enterprises. Part II: the aging heart in health: links to heart disease. Circulation 107 (2003) 346-354
26. Neaton J., Wentworth D., Sherwin R., Kittner S., Kuller L., Stamler J., and The MRFIT Research Group. Comparison of 10 year coronary and cerebrovascular disease mortality rates by hypertensive status for Black and non-Black men screened in the Multiple Risk Factor Intervention Trial (MRFIT) [abstract]. Circulation 80 (1989) II-300
27. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
28. Dahlöf B., Sever P.S., Poulter N., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366 (2005) 895-906
29. White W.B. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 6 (2001) 63-72
30. Merz C.N.B., Shaw L.J., Reis S.E., et al., WISE Investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 47 (2006) 21-30
31. Yancy C.W., and Sica D.A. Cardiovascular disease in African-Americans. J Clin Hypertens 6 4 suppl 1 (2004) S54-S56
32. Kikkawa R., Araki S., Haneda M., Kajiwara N., Hidaki H., and Shigeta Y. Hypertension and the development of complications in noninsulin dependent diabetes mellitus in Japan. J Am Soc Nephrol 3 (1992) 5120-5125
33. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
34. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572 erratum JAMA 2003;290:197
35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202 (1967) 1028-1034
36. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 (1970) 1143-1152
37. Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet 1 (1980) 1261-1267
38. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 291 (1985) 97-104
39. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 45 (1972) 991-1004
40. Berglund G. The meaning of clinical trials. Controversies in the treatment of hypertension. In: Laragh J.N., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis, and management (1990), Raven Press Ltd, New York, New York 1955-1965
41. Hansson L., Zanchetti A., Carruthers S.G., et al., HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
42. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
43. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
44. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 314 (1986) 1547-1552
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
46. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
47. Merit-HF Study Group. Effect of metroprolol CR/XL in chronic heart failure: Metroprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
48. Packer M., Coats A.J., Fowler M.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect on carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med 344 (2001) 1651-1658
49. Anand I.S., Tam S.W., Rector T.S., et al. Influence of blood pressure on the effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49(1 (2007) 32-39
50. Sever P.S., Dahlöf B., Poulter N.R., et al., ASCOT Investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 361 (2003) 1149-1158
51. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
52. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
53. Svensson P., de Faire U., Sleight P., Yusuf S., and Östergren J. Comparative effects of ramipril on ambulatory and office blood pressure: A HOPE substudy. Hypertension 38 (2001) e28-e32
54. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
55. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein G.D., and Weingarten S.R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 (2004) 693-704
56. Lonn E., Yusuf S., Dzavik V., et al., SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
57. Lonn E., Shaikholeslami R., Yi Q., et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 43 (2004) 2200-2206
58. Wong M., Staszewsky L., Latini R., et al., Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40 (2002) 970-975
59. Leibovitz E., Beniashvili M., Zimlichman R., Freiman A., Shargorodsky M., and Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 16 (2003) 715-718
60. Mason R.P., Kalinowski L., and Madajka M. Combined effects of amlodipine and atorvastatin on endothelial dysfunction in vitro [abstract]. Circulation 112 (2005) II-203
61. Metra M., Nodari S., Parrinello G., Giubbini R., Manca C., and Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 145 (2003) 292-299
62. Schiffrin E.L., Deng L.Y., and Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23 (1994) 83-91
63. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283 (2000) 1967-1975
64. Cintron G., Johnson G., Francis G., Cobb F., Cohn J.N., and V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure [abstract]. Circulation 87 (1993) VI-1723
65. Devereux R.B., Dahlöf B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
66. Dahlöf B., Sever P.S., Poulter N., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366 (2005) 895-906
67. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
68. Julius S., Kjeldsen S.E., Weber M., et al., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
69. Julius S., Nesbitt S.D., Egan B.M., et al., Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
70. Cohn J.N., Hoke L., and Whitwam W. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 146 (2003) 679-685
71. Cohn J.N., Duprez D.A., and Grandits G.A. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension 46 (2005) 217-220
72. Adams K.F., Boehmer J.P., Deedwania P., et al. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 (2006) 10-38